Circio Holding ASA

Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds

Oslo, 20 June 2025: Reference is made to the stock exchange announcement by

Circio Holding ASA (OSE:CRNA) (the "Company") on 17 June 2025, regarding the

requested conversion of convertible bonds by Atlas Special Opportunities, LLC.

The share capital increase has now been registered with the Norwegian Register

of Business Enterprises (Nw. Foretaksregisteret). The Company's new share

capital is NOK 61,345,650.00 divided into 102,242,750 shares, each with a

nominal value of NOK 0.60.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Lubor Gaal, CFO

Phone: +34 683343811

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing powerful circular RNA

vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression

platform for novel DNA, RNA and viral therapeutics. The proprietary circVec

technology is based on a modular genetic cassette design for efficient

biogenesis of multifunctional circRNA inside cells, which can be deployed in

multiple therapeutic settings, including genetic medicine, cell therapy and

chronic disease. The circVec platform has demonstrated up to 15-fold enhanced

and more significantly more durable protein expression vs. classic mRNA vector

systems and has the potential to become a new gold-standard platform

technology for nucleic acid and viral therapeutics in the future. The circRNA

R&D activities are being conducted by the wholly owned subsidiary Circio AB

based at the Karolinska Institute in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology

program, TG01, through external collaborations. TG01 targets RAS-mutated

cancers and is being tested in two clinical trials in Norway and the USA run

through academic networks and industry partnerships. TG01 is a therapeutic

peptide vaccine adjuvanted by STIMULON QS-21 licensed from Antigenics Inc, a

wholly owned subsidiary of Agenus Inc. STIMULON is a trademark of SaponiQx

Inc., a subsidiary of Agenus

AI Terminal